NASDAQ:EDSA (Edesa Biotech, Inc.)

Edesa Biotech, Inc. is biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. The company's clinical pipeline is focused on two therapeutic areas: Medical Dermatology and Respiratory. The company's drug candidates include EB06, a monoclonal antibody, being developed as a therapy for Vitiligo, and EB05 (paridiprubart), a host-directed therapeutic under development for respiratory diseases, including Acute Respiratory Distress Syndrome (ARDS).